SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

FDA approval of Rasonque (daraxonrasib) for metastatic pancreatic cancer is driving attention, with traders highlighting its first-in-class RAS-targeted mechanism and strong survival results as a potential commercial breakthrough. Despite bullish views on the launch and broader oncology pipeline, some investors are debating the stocks elevated valuation, treatment cost and access, while others interpret the muted pullback as profit-taking or a sell-the-news reaction.

ProShares Trust II - ProShares UltraShort Bloomberg Crude Oil -2x Shares

ProShares UltraShort Bloomberg Crude Oil

Speculation around U.S.-Iran negotiations and a potential reopening of the Strait of Hormuz is driving attention, with traders positioning for crude to fall if de-escalation restores flows and supply rises. Others expect continued disruptions to keep oil elevated and warn that SCOs daily reset and volatility decay can weaken returns even when crude declines.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

A bearish BMF short report criticizing SELLASs REGAL Phase 3 design, statistical power, dilution and valuation triggered the selloff and intensified debate ahead of the 80th event and topline data. Bulls largely dismiss the report as a disclosed short-side thesis and point to prolonged patient survival and prior interim reviews, while bears remain concerned that the delayed event and quiet period could precede unfavorable results.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

A sizable at-the-market share offering announced around the quarterly results has become the dominant catalyst, with traders concerned about dilution, potential selling pressure, and uncertainty over why the company is raising cash despite strong operating performance. Some investors view the selloff as a temporary overreaction and remain bullish on Innodatas AI-data growth, while others are focused on customer concentration and bearish technical momentum.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Anticipated LUNC supply burnslinked by traders to Binance activity, the Jane Street legal dispute, and Market Module 2.0along with a possible USTC repeg are driving bullish speculation around a Terra Classic recovery. Skeptics point to LUNCs large supply, thin liquidity, repeated pullbacks, and unverified exchange-listing or burn claims, keeping the debate focused on whether the rally is sustainable.

Vistra Corp. is a holding company, which engages in the provision of electricity and power generation. It operates through the following segments: Retail, Texas, East, West, and Asset Closure. The Retail segment includes sale of electricity and natural gas to residential, commercial, and industrial customers. The Texas and East segments are involved in electricity generation, wholesale energy sales and purchases, commodity risk management activities, fuel production and fuel logistics management. The West segment represents the company's electricity generation operations in CAISO. The Asset Closure segment refers to the decommissioning and reclamation of retired plants and mines. The company was founded in 1882 and is headquartered in Irving, TX.

Vistra Corp

Q2 earnings have driven attention, with traders divided between concerns over weaker headline revenue and EPS and optimism that hedge-related losses masked healthy operations, improving adjusted EBITDA, and reaffirmed guidance. Bulls continue to cite Vistras long-term power agreements and exposure to AI/data-center electricity demand, while the stocks persistent downtrend has fueled skepticism.

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

Kura Oncology Inc

Repeated open-market share purchases by CEO Troy Wilson are the primary catalyst, with traders viewing the insider buying as a confidence signal following Kuras Q2 update. The community is broadly bullish and also focused on KOMZIFTIs commercial traction and upcoming AML data, while buyout and short-covering theories remain speculative amid concerns about valuation and cash burn.

NANO Nuclear Energy, Inc. is a microreactor and nuclear technology company, which provides supply energy services. Its products in technical development are ZEUS, a solid core battery reactor, and ODIN, a low-pressure coolant reactor. The company is founded by Jiang Yu in February, 2022 and is headquartered in New York, NY.

Nano Nuclear Energy Inc.

NNE is drawing attention as part of a broader nuclear/SMR rotation tied to AI data-center power demand, U.S. nuclear policy, and recent company developments including Air Force work, regulatory progress, and fuel/logistics initiatives. Traders remain divided, with bulls citing long-term commercialization potential and bears pointing to its pre-revenue status, execution risk, dilution concerns, and sector-wide weakness.

JD.com, Inc. is a technology-driven E-commerce company, which engages in the sale of electronics products and general merchandise products, including audio, video products, and books. It operates in the following segments: JD Retail, JD Logistics, and New Businesses. The JD Retail segment offers online retail, online marketplace, and marketing services. The JD Logistics segment includes internal and external logistics businesses. The New Businesses segment is composed of JD Property, Jingxi, overseas businesses and technology initiatives. The company was founded on June 18, 1998, by Qiang Dong Liu and is headquartered in Beijing, China.

JD.com Inc - ADR

JDs latest quarterly results are the dominant focus: traders note earnings and profitability were better than expected, but revenue declined amid weak Chinese consumption and intense e-commerce competition, prompting a sharp selloff. The community is split between viewing the reaction as an overdone, value-driven buying opportunity supported by buybacks and logistics growth, and seeing it as confirmation of broader China and consumer-sector weakness.

The Last Play is Crypto’s 401k.  RETIRE is more than a coin; it’s The Last Play. We are a community dedicated to breaking free from the grind and building true generational wealth. With RETIRE, our mission is simple yet profound: to provide a pathway to retire yourself and secure financial freedom for your bloodline. While others chase hype and trends, we’re focused on creating a legacy that lasts beyond the typical cycle. RETIRE is about making the one move that matters, with a vision for long-term value, freedom, and impact. This isn’t just a meme —it’s a purpose-driven commitment to building a legacy.

The Last Play

Community-led promotion of RETIRE as a tokenized 401(k) and coordinated weekly DCA buying has driven renewed attention, alongside claims of strong gains and rising activity. Supporters view it as a long-term, mission-driven meme coin, while skeptics point to low liquidity, selling pressure, and pump-and-dump or rug-pull risks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AbbVies acquisition of Apogee Therapeutics is driving attention, with traders focusing on the deals potential to strengthen its immunology and respiratory pipeline. Debate centers on the strategic value of the purchase versus added debt, dilution, and the long timeline to earnings contribution, alongside broader healthcare-sector rotation and bullish technical momentum.

AbbVie Seeks EU Nod for Subcutaneous Skyrizi in Crohn's Disease

ABBV seeks EU approval for a subcutaneous Skyrizi induction option in Crohn's disease, potentially adding convenience for patients.

FDA Nods Lilly-Roche's Alzheimer's Blood Test: Healthcare ETFs to Track Now 

 FDA clearance of Lilly and Roche's Alzheimer's blood test highlights a growing diagnostics market and four healthcare ETFs to watch.

AbbVie Submits Regulatory Application to EMA for SKYRIZI (risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease

AbbVie Submits Regulatory Application to EMA for SKYRIZI (risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease AbbVie Submits Regulatory Application to EMA for SKYRIZI (risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active...

If You Invested $100 In AbbVie Stock 10 Years Ago, You Would Have This Much Today

AbbVie (NYSE:ABBV) has outperformed the market over the past 10 years by 1.74% on an annualized basis producing an average annual return of 15.14%. Currently, AbbVie has a market capitalization of $468.74 billion.read more...

Billionaire Ken Griffin Increased His Stake in This Dividend King by 547% in Q2. Wall Street Thinks It's Still a Buy.

Key PointsThe hedge fund manager bought some 2.7 million shares of AbbVie stock in the second quarter...

How Did ABBV's Oncology Sales Hold Up in Q2 Amid Imbruvica Headwinds?

AbbVie's oncology sales fall 2.4% in Q2 as Imbruvica declines, while Venclexta and newer drugs help offset the pressure.

LLY vs. ABBV: Which Stock Has the Stronger Growth Prospects?

Lilly and AbbVie bring different growth drivers, pipelines and risks to the table. See which drugmaker offers the more compelling 2026 upside.

RGNX Stock Slumps 25% on FDA Clinical Hold for RGX-121 Gene Therapy

REGENXBIO stock plunges 25% after the FDA places a clinical hold on RGX-121 for MPS II, following asymptomatic spine MRI findings in five participants.

Is SYRE a Buy Now as Clinical Catalysts Clash With Valuation Risk?

Spyre has a broad clinical pipeline and cash runway, but elevated valuation makes upcoming readouts critical to its investment case.

Can Spyre's SPY772 HS Study Broaden Its Growth Story Beyond Core IBD?

SYRE expands into HS with SPY772, testing whether dual-pathway inhibition can strengthen outcomes in SKYLIGHT.

• Reported GAAP EPS of $2.03 up 290.38% YoY
• Reported revenue of $16.99B up 10.16% YoY
• AbbVie is updating its 2026 adjusted diluted EPS guidance range from $13.91 - $14.11 to $13.87 - $14.07, reflecting an anticipated $0.14 dilutive impact from the proposed acquisition of Apogee Therapeutics.

AbbVie faces significant declines in its Humira and Imbruvica portfolios, while the proposed Apogee Therapeutics acquisition introduces execution, integration, and clinical development risks that could impact future operational results.

AbbVie achieved robust revenue growth in its immunology and neuroscience portfolios, while the strategic acquisition of Apogee Therapeutics bolsters the company's long-term pipeline and immunology leadership position.

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Abbvie Inc

SLS Stock Heads For Worst Month In Over 2 Years — But Retail Bulls ‘Hold’ For AML Readout And Buyout Hopes

Equity

Bullish Sentiment

Track ABBV stock price, charts, news and real-time market activity on Stocktwits. Join the ABBV message board to follow investor discussions, retail trader sentiment, bullish and bearish signals around AbbVie Inc stock.

ABBV Stock Price Today - Abbvie Inc News, Charts, Retail Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

The S&P 500 ($SPY) is headed towards a positive week. What do you think the index's return will look like next week? Vote and explain your reasoning in the comments.

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Earnings

NewFutures

Fundamentals

Info

ABBV Single Stock Futures